DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: veliparib (ABT-888)

First Posted Date: 2014-08-07

Last Posted Date: 2018-05-07

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT02210663

Locations: 🇯🇵
Site Reference ID/Investigator# 128056, Hidaka-shi, Japan
🇯🇵
Site Reference ID/Investigator# 128057, Tokyo, Japan
🇯🇵
Site Reference ID/Investigator# 129976, Hyogo, Japan

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Phase 3

Completed

Conditions: Hepatitis C Virus
Compensated Cirrhosis
End-stage Renal Disease
Chronic Hepatitis C
Severe Renal Impairment

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir
Drug: Ribavirin

First Posted Date: 2014-08-01

Last Posted Date: 2017-11-09

Lead Sponsor: AbbVie

Target Recruit Count: 68

Registration Number: NCT02207088

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Myelogenous Leukemia
Treatment Naive AML

Interventions: Drug: ABT-199
Drug: Posaconazole
Drug: Azacitidine
Drug: Decitabine

First Posted Date: 2014-07-30

Last Posted Date: 2023-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 212

Registration Number: NCT02203773

Locations: 🇺🇸
Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States

and more 20 locations

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab

First Posted Date: 2014-07-30

Last Posted Date: 2019-11-08

Lead Sponsor: AbbVie

Target Recruit Count: 110

Registration Number: NCT02203851

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

Phase 4

Completed

Conditions: Rheumatoid Arthritis
Musculoskeletal and Connective Tissue Diseases

Interventions: Other: Placebo
Biological: Adalimumab

First Posted Date: 2014-07-24

Last Posted Date: 2019-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 149

Registration Number: NCT02198651

Locations: 🇨🇦
St. Joseph's Healthcare /ID# 149233, Hamilton, Ontario, Canada
🇺🇸
Westlake Medical Research (WMR) Clinical Trials /ID# 155386, Thousand Oaks, California, United States
🇩🇪
Asklepios Klinik /ID# 129146, Bad Abbach, Germany

and more 67 locations

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Adalimumab
Drug: Methotrexate

First Posted Date: 2014-07-22

Last Posted Date: 2018-03-19

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02196701

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Adalimumab

First Posted Date: 2014-07-09

Last Posted Date: 2018-11-14

Lead Sponsor: AbbVie

Target Recruit Count: 252

Registration Number: NCT02185014

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2014-06-19

Last Posted Date: 2022-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 615

Registration Number: NCT02167945

Locations: 🇺🇸
St. Josephs Hospital and Med Center /ID# 127800, Phoenix, Arizona, United States
🇺🇸
Univ of Colorado Cancer Center /ID# 126568, Aurora, Colorado, United States
🇺🇸
Encore Borland-Groover Clinical Research /Id# 127781, Jacksonville, Florida, United States

and more 45 locations

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Veliparib Placebo
Drug: Veliparib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2014-06-16

Last Posted Date: 2025-02-19

Lead Sponsor: AbbVie

Target Recruit Count: 513

Registration Number: NCT02163694

Locations: 🇺🇸
University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States
🇺🇸
Allegheny General Hospital /ID# 135094, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States

and more 216 locations

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

Phase 4

Completed

Conditions: Moderate to Severe Crohn's Disease

Interventions: Biological: adalimumab

First Posted Date: 2014-05-28

Last Posted Date: 2018-03-01

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT02148718

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy